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osting by EAbstract Background: Trastuzumab use in Her-2-neu positive breast cancer patients is the current
standard of care. Trastuzumab is known to result in cardiotoxicity. The toxicity seems to be dose-
dependent, and serial cardiology assessment with echocardiography is advised. In spite of this,
patients do develop cardiotoxicity and identiﬁcation of patients at high risk and, if possible, any
preventive means is of paramount importance.
Methods: We performed a retrospective analysis of medical records of all breast cancer patients
presenting at King Khalid University Hospital from 02/2006 to 06/2009 and receiving adjuvant
trastuzumab on the basis of either immunohistochemistry showing Her-2-neu (3+) or FISH posi-
tive Her-2-neu receptor status. Patients received adjuvant trastuzumab at an 8 mg/kg loading dose
over 90 min, followed by 6 mg/kg every 3 weeks. A repeat multigated acquisition scan/echocardio-
gram was done after every 4 courses. Patient characteristics, such as age, menopausal status, tumor
size, lymph nodal status, distant metastasis at presentation, grade of tumor, estrogen and proges-
terone receptor status, comorbid conditions (diabetes, hypertension, ischemic heart diseases), che-
motherapy received, total dose of trastuzumab, timing of cardiotoxicity, and number of patients
having cardiotoxicity, were recorded. A patient was said to have cardiotoxicity if the ejection frac-
tion dropped by 10% of the original value or if there was a drop in the ejection fraction below the
normal value.
Results: A total number of 98 breast cancer patient records were analyzed in this study. A total of
11 patients developed cardiotoxicity, evident by a drop in the ejection fraction on an echocardio-
gram. Seven patients out of 11 had a drop in ejection fraction below 10% of the baseline value,rtment of Medicine (38), King
2925, Riyadh 11461, Saudi
6 1 4671546.
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134 A. Aldiaband 4 patients out of 11 had a drop in ejection fraction below normal values. A total of 5 patients
became symptomatic with dyspnea on exertion, with 2 being of NYC Class I, 2 being of NYC Class
II, 1 being of NYC Class III, and none being of NYC Class IV. Seven patients out of 11 with car-
diotoxicity had diabetes and hypertension as comorbid conditions. Patients receiving doxorubicin in
neoadjuvant and adjuvant settings were associated with cardiotoxicity. The total dose of trast-
uzumab had a strong association, with the patient getting more than 60 mg/kg in a 3-weekly fashion
being associated with cardiotoxicity.
Conclusions: Trastuzumab is associated with signiﬁcant cardiotoxicity. Asymptomatic and symp-
tomatic cardiotoxicity and toxicity seem to be dose-dependent in an adjuvant setting. At the end
of therapy, more frequent than usual monitoring of cardiac function is suggested to prevent this
toxicity.
ª 2010 King Saud University. All rights reserved.1. Introduction
The human epidermal growth factor receptor 2 (Her-2-neu/
erb-B-2) is expressed in the adult myocardium and plays an
important role in the modulation of anthracycline-associated
cardiotoxicity (Suter et al., 2007; Tripathy and Burstein,
1998; Guglin et al., 2008). Trastuzumab is an antibody against
the Her-2-neu (c-erb-B-2) protein. This product has received
considerable attention of late, based on its apparently modest
toxicity and its efﬁcacy in treating Her-2-expressing metastatic
breast cancer. Several large multicenter trials have been
conducted studying trastuzumab as either a single agent or
in combination with chemotherapy. The toxicity proﬁle of
trastuzumab was also characterized. A common side effect in-
cluded infusion reactions consisting of transient fever and
chills, which occur in 25–30% of patients and are more likely
to be seen with the ﬁrst cycle of administration only. Other side
effects include possible exacerbation of some chemotherapy-
related side effects, including GI toxicity and myelosuppres-
sion. However, most attention has focused on the possible car-
diac side effects of trastuzumab therapy, particularly in
combination with chemotherapy (Montemurro et al., 2008).
Cardiac dysfunction (CD) is deﬁned as the onset of cardiac
symptoms or an asymptomatic decrease in EF of 10% or
more. The mechanisms for CD remain unclear. Trastuzumab
beneﬁts patients with metastatic breast cancer and improves
disease-free and overall survival after adjuvant chemotherapy
(Montemurro et al., 2008; Telli et al., 2007) and BCIRG 006
clinical overview. However, trastuzumab treatment is also
associated with congestive heart failure and cardiac dysfunc-
tion. Patients receiving trastuzumab should undergo monitor-
ing for deteriorating left ventricular function prior to
trastuzumab treatment, and frequently during and after trast-
uzumab treatment. Discontinue trastuzumab for clinically sig-
niﬁcant decreases in left ventricular function (CHF). In
patients with asymptomatic declines in LVEF, trastuzumab
may be held and resumed up to 3 times, When trastuzumab
is withheld, it may be resumed if, within 4–8 weeks, (1) the
LVEF returns to normal limits and (2) the absolute decrease
from baseline is <15% points. Trastuzumab should be perma-
nently discontinued if (1) a persistent (>8 weeks) LVEF de-
cline is observed or (2) trastuzumab dosing is withheld on
more than 3 occasions for cardiomyopathy (Telli et al., 2007).
The objectives of this retrospective study were to evaluate
cardiotoxicity with trastuzumab in breast cancer patients and
to determine the long-term safety of this drug.2. Methods
We performed a retrospective analysis of the medical records
of all breast cancer patients presenting at King Khalid Univer-
sity Hospital from 1993 to 2008 and receiving trastuzumab
(Herceptin, Genentech) on the basis of either immunohisto-
chemistry showing Her-2-neu (3+) or FISH positive Her-2-
neu receptor status. Patients characteristics, such as age,
menopausal status, tumor size, lymph nodal status, distant
metastasis at presentation, grade of tumor, estrogen and pro-
gesterone receptor status, comorbid conditions (diabetes,
hypertension, and ischemic heart diseases), chemotherapy re-
ceived, total dose of trastuzumab, timing of cardiotoxicity,
and number of patients having cardiotoxicity, were recorded.
Patients on trastuzumab therapy were evaluated before each
course for subjective symptoms of heart failure and for objec-
tive examination to rule it out. A MUGA/echocardiogram was
repeated after 4 courses of trastuzumab to look for a drop in
the EF. A patient was said to have cardiotoxicity if the ejection
fraction (EF) dropped by 10% of the original value or if there
was a drop in the EF below the normal value 16.
3. Results
Total number of patients included were 98 age ranged between
20–80 years. 28% were diabetic, 33% were hypertensive and
24% had dyslipidemia. 58% of patients had their lesion on
the right side. None of the patients had coronary artery disease
at the start of therapy. Most patients had received doxorubi-
cin-based chemotherapy either in the form of the TAC chemo-
therapy protocol (docetaxol, cyclophosphamide, F-FU) or the
AC (doxorubicin, cyclophosphamide) chemotherapy protocol,
followed by taxotere. Total cumulative dose of doxorubicin
was calculated for each patient before starting trastuzumab
therapy. Eighty-nine percent of patients received <300 mg/
m2 of doxorubicin before trastuzumab. Baseline multigated
acquisition scan (MUGA)/echocardiogram showed EF within
normal limits (Fig. 1).
It was observed that cardiotoxicity was dose-dependent as
most of the patients had a drop in the EF after receiving a
>60 mg/kg dose (after the 10th course of therapy), and none
of the patients had idiosyncratic cardiotoxicity. Symptomatic
cardiotoxicity developed late in the course of treatment
(Fig. 2) (Tan-Chiu and Piccart, 2002). Seventeen percent of pa-
tients discontinued trastuzumab during treatment, 11 because
of cardiotoxicity and 6 for noncardiac reasons, out of which
Figure 3 Cardiotoxicity according to NYC classiﬁcation.
Figure 4 Recovery of left ventricular function after trastuzumab
therapy.
Figure 1 Cardiotoxicity over 1 year of trastuzumab therapy.
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metastatic disease (brain metastasis in 3 and liver metastasis
in 1) (Fig. 3).
Out of 11 patients, 5 patients had symptomatic heart fail-
ure: 2 patients had NYC Class I, 2 patients had NYC Class
II, 1 patient had NYC Class III, and no patients had NYC
Class IV symptomatic heart failure (Fig. 4). In all patients with
cardiotoxicity, trastuzumab therapy was withheld; the case was
referred to a cardiologist, and appropriate treatment com-
menced. Patients were reviewed weekly for symptomatic
improvement and had a 2-weekly echocardiogram initially
for 1 month and then monthly until recovery of the EF. None
of the patients required intensive care admission, and there
were no cases of therapy-associated mortality.
It was observed that recovery of the EF was dependent on
symptomatology as an asymptomatic drop in the EF 10–15%
below baseline level recovered in 4–6 weeks, while for an EF
drop below normal level (EF = 55%), recovery usually took
8–10 weeks if the patient was asymptomatic. A symptomatic
NYC Class I drop in the EF took 38–40 weeks to recover,
and an NYC Class II drop in the EF took 60–65 weeks to re-
cover. An NYC Class III symptomatic drop in the EF took
80 weeks to recover in our patient; no patient had NYC ClassFigure 2 Reasons for disconIV, which is reported to take even more time for recovery
(>90 weeks) (Fig. 5).tinuation of trastuzumab.
Figure 5 Types of chemotherapy drugs before or with trastuzumab.
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Our study attempted to address the concept of reversibility
of acute CD and underlined the importance of lesser degrees
of asymptomatic left ventricular dysfunction. Cardiac systolic
function decreases during trastuzumab administration. There
seems to be full or partial recovery after its withdrawal, with
or without heart failure medications. Although the LVEF
generally recovers after trastuzumab is stopped, it often does
not recover to baseline level, and these patients are often
maintained on cardiac medications. It is possible therefore
that the damage will be sustained and that any damage
may worsen over time and/or the myocardium may be more
susceptible to future damage from other cardiac events. It is
therefore possible that the long-term effects will become
more clinically relevant than the acute effects (Telli et al.,
2007).
In our study, depending on the severity of LVEF drop
at 28–95 weeks, patients took longer to recover EF, but
EF did not recover to pretreatment levels in a number of pa-
tients, and a few patients continued to require heart failure
medications long after that, questioning the concept of
reversibility.
In our study, trastuzumab had to be discontinued in 17 pa-
tients: 11 had cardiotoxicity, 1 patient had a noncardiogenic
reason for withdrawal, 4 patients had progression of disease,
and 1 patient refused therapy.5. Conclusions
In conclusion cardiotoxicity seems to be dose-dependent as
most patients had a drop in EF, symptomatic or asymptom-
atic, after receiving more than 10 courses of treatment. It is
suggested that more regular than usual monitoring of cardiac
function at the end of therapy is needed.
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